Zacks Investment Research lowered shares of Diplomat Pharmacy (NYSE:DPLO) from a buy rating to a hold rating in a report released on Wednesday.
According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
DPLO has been the subject of a number of other reports. Robert W. Baird lowered shares of Diplomat Pharmacy from an outperform rating to a neutral rating and lowered their price objective for the stock from $24.00 to $18.00 in a research note on Thursday, November 16th. Leerink Swann raised shares of Diplomat Pharmacy from a market perform rating to an outperform rating and set a $23.00 price objective for the company in a research note on Monday, December 11th. Lake Street Capital initiated coverage on shares of Diplomat Pharmacy in a research note on Friday, February 9th. They issued a buy rating and a $35.00 price objective for the company. Credit Suisse Group raised shares of Diplomat Pharmacy from an underperform rating to a neutral rating and set a $28.00 price objective for the company in a research note on Thursday, January 25th. Finally, Mizuho set a $25.00 price objective on shares of Diplomat Pharmacy and gave the stock a hold rating in a research note on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of Hold and a consensus price target of $23.95.
Shares of Diplomat Pharmacy (DPLO) opened at $23.26 on Wednesday. Diplomat Pharmacy has a one year low of $13.39 and a one year high of $27.78. The firm has a market cap of $1,601.99, a PE ratio of 30.21 and a beta of 1.06. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18.
Hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its position in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after buying an additional 2,794 shares during the last quarter. Advisors Preferred LLC purchased a new stake in shares of Diplomat Pharmacy during the fourth quarter valued at about $162,000. SG Americas Securities LLC purchased a new stake in shares of Diplomat Pharmacy during the third quarter valued at about $191,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Diplomat Pharmacy during the third quarter valued at about $216,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Diplomat Pharmacy during the fourth quarter valued at about $244,000. 73.44% of the stock is owned by institutional investors and hedge funds.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.